CBD drug manufacturer GW Pharmaceuticals saw a significant net loss in the last quarter, despite growth and sales of its cannabis-derived pharmaceutical drugs going to plan.
The company reported a loss of $71.9m for the quarter ending 31st December 2018, compared with $61.8m for the same quarter in 2017.
Restricted content. Do you want to read more?
The data or analysis report you have tried to access is restricted to our subscribers. We invite you to take a free trial below where you will get access to a limited set of our content.
You can find available reports for purchase in our
online store. Reports not listed in the store are available under request. If you are interested in a subscription, get in contact to discuss our subscription plans or to upgrade your current access.
CBD-Intel provides premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets.
We provide our clients with the tools to navigate this fast-moving sector, tailor their business strategy, optimise resources and make informed decisions.